BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report sent to investors on Friday. The brokerage issued a sell rating on the medical technology company’s stock.

BIOLASE Trading Down 13.3 %

Shares of BIOL opened at $0.01 on Friday. The firm’s fifty day simple moving average is $0.01 and its two-hundred day simple moving average is $0.01. BIOLASE has a 12 month low of $0.02 and a 12 month high of $1.94. The stock has a market capitalization of $260,574.60, a P/E ratio of 0.00 and a beta of 0.67.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.